Sarepta Therapeutics Coverage Initiated by Analysts at Cowen and Company (SRPT)
Investment analysts at Cowen and Company initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a note issued to investors on Tuesday. The firm set an “outperform” rating and a $44.00 price target on the stock. Cowen and Company’s price target would indicate a potential upside of 96.60% from the company’s current price.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 22.35 on Tuesday. Sarepta Therapeutics has a 52 week low of $12.12 and a 52 week high of $55.61. The stock’s 50-day moving average is $22.95 and its 200-day moving average is $27.97. The company’s market cap is $914.6 million.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings data on Thursday, August 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.09. The company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $4.30 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share. Sarepta Therapeutics’s revenue was down 12.5% compared to the same quarter last year. On average, analysts predict that Sarepta Therapeutics will post $-3.51 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Oppenheimer initiated coverage on shares of Sarepta Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $45.00 price target on the stock. Separately, analysts at Deutsche Bank reiterated a “positive” rating on shares of Sarepta Therapeutics in a research note on Wednesday, July 30th. Finally, analysts at WBB Securites upgraded shares of Sarepta Therapeutics from a “speculative buy” rating to a “buy” rating in a research note on Tuesday, July 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and an average price target of $40.00.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.